{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.8","upperLimit":"2.9","value":"2.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"}],"units":"Participants"}],"description":"Progression-free survival (PFS) was defined as the time from first treatment to either the date of first disease progression (PD) or the date of death (for whatever reason), whichever came first. Patients alive and without disease progression were censored at the date of the last visit/contact.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients with non-operable and progressing metastatic cutaneous melanoma, received up to 24 doses of GSK2241658A Cancer Immunotherapeutic, provided that at each tumor evaluation time point, the clinical criteria to continue the treatment were met, including patients having a clinical response.","id":"OG000","title":"NY-ESO 1 Group"}],"paramType":"MEDIAN","populationDescription":"The analysis was performed on the total treated cohort (TTC), which included all subjects who received at least one dose of the Antigen-Specific Cancer Immunotherapeutic (ASCI) treatment.","reportingStatus":"POSTED","timeFrame":"From first treatment administration (i.e. at Week 0) until the last tumor evaluation (i.e. at Month 49)","title":"Progression-free Survival (PFS) Rate","type":"SECONDARY","unitOfMeasure":"Months"}